Glycyl-glycyl-phenylalanyl-glycin | 92654-02-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glycyl-glycyl-phenylalanyl-glycin
• 英文别名: glycylglycylphenylalanylglycine；{2-[2-(2-Aminoacetamido)acetamido]-3-phenylpropanamido}acetic acid；2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid
• CAS: 92654-02-9
• 化学式: C₁₅H₂₀N₄O₅
• 分子量: 336.348
• InChiKey: HXUVTXPOZRFMOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  151
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• [EN] NEODEGRADER CONJUGATES<br/>[FR] CONJUGUÉS DE TYPE NEODEGRADER
  申请人：ORUM THERAPEUTICS INC

  公开号：WO2021198965A1

  公开（公告）日：2021-10-07

  The present disclosure provides neoDegraders and neoDegraders conjugated to binding moieties. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.

  本公开提供了与结合基团结合的neoDegraders和neoDegraders。还提供了包含这些结合物的组合物。这些化合物和组合物对于治疗患有疾病或症状的受试者（例如癌症）是有用的。
• [EN] ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES<br/>[FR] MÉDICAMENTS LIEURS D'ANTIFOLATE ET CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：BYONDIS BV

  公开号：WO2022008419A1

  公开（公告）日：2022-01-13

  The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.

  本发明涉及新型抗叶酸连接剂药物，包括这种抗叶酸连接剂的共轭物，并将其用于治疗疾病，如癌症、自身免疫和传染病，可选择性地与其他治疗剂联合使用。
• [EN] NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES<br/>[FR] CONJUGUÉS NÉODÉGRADEUR-ANTICORPS ANTI-CD33
  申请人：ORUM THERAPEUTICS INC

  公开号：WO2022254377A1

  公开（公告）日：2022-12-08

  The present disclosure provides neoDegraders conjugated to anti-CD33 antibodies. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.

  本公开提供了与抗CD33抗体结合的neoDegraders。还提供了包括这些结合物的组合物。这些化合物和组合物可用于治疗需要治疗的主体的疾病或状况，例如癌症。
• DDS COMPOUND AND PROCESS FOR THE PREPARATION THEREOF
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1298145A1

  公开（公告）日：2003-04-02

  A DDS compound in which amino group at 1-position of (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-10,13(9H,15H)-dione as a drug compound is bound to a carboxyl group of a carboxymethyldextran polyalcohol with a spacer containing one amino acid or two to eight amino acids linked by peptide bond(s); characterized in that an introduced amount of residue of the drug compound is in a range of from 3.2% to 8.4% by weight; a weight-average molecular weight of the carboxymethyldextran polyalcohol is in a range of from 240,000 to 480,000; and degree of carboxymethylation is in a range of from 0.14 to 0.47; and a method for preparing said DDS compound, which comprises the steps of, for example, adding an aqueous solution containing sodium periodate to an aqueous solution containing dextran at a temperature of 4°C ± 2°C to oxidize the dextran, and then adding the resulting reaction mixture to an aqueous solution containing sodium borohydride at a temperature not higher than 15°C to obtain a dextran polyalcohol.

  一种 DDS 化合物，其中 (1S,9S)-1-氨基-9-乙基-5-氟-2,3-二氢-9-羟基-4-甲基-1H,12H-苯并[de]吡喃并[3',4'：6,7]-吲哚利嗪并[1,2-b]喹啉-10,13(9H,15H)-二酮作为药物化合物与羧甲基二葡聚糖多元醇的羧基结合，羧甲基二葡聚糖多元醇含有通过肽键连接的一个氨基酸或二至八个氨基酸的间隔物；其特征在于，药物化合物的引入残留量范围为3.2% 至 8.4% (按重量计)；羧甲基二葡聚糖多元醇的重量-平均分子量在 240,000 至 480,000 之间；羧甲基化程度在 0.14 至 0.47 之间；以及制备所述羧甲基二葡聚糖多元醇的方法。47；以及制备所述DDS化合物的方法，该方法包括以下步骤，例如，在4℃±2℃的温度下，将含有高碘酸钠的水溶液加入到含有葡聚糖的水溶液中，使葡聚糖氧化，然后在不高于15℃的温度下，将得到的反应混合物加入到含有硼氢化钠的水溶液中，得到葡聚糖多元醇。
• NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3848054A1

  公开（公告）日：2021-07-14

  Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives.

  希望开发出具有 STING 激动剂活性的新型 CDN 衍生物；以及使用新型 CDN 衍生物治疗与 STING 激动剂活性相关疾病的治疗剂和/或治疗方法。还希望开发一种治疗剂和/或治疗方法，能够将新型 CDN 衍生物特异性地输送到靶细胞和器官，以治疗与 STING 激动剂活性相关的疾病。本发明提供了具有强效 STING 激动剂活性的新型 CDN 衍生物，以及包括新型 CDN 衍生物的抗体-CDN 衍生物共轭物。